Teva Pharmaceutical Industries (TEVA) Other Non-Current Liabilities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other Non-Current Liabilities for 18 consecutive years, with $3.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities fell 3.73% year-over-year to $3.8 billion; the trailing twelve-month figure through Jun 2026 stood at $3.8 billion (down 3.73% YoY), and the FY2025 full-year result was $3.8 billion, down 5.46% from the prior year.
• Other Non-Current Liabilities advanced to $3.8 billion in Q2 2026 per TEVA's latest filing, from $3.7 billion in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.4 billion in Q2 2024 and bottomed at $3.3 billion in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $3.9 billion across 5 years, with a median of $3.9 billion in 2022.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities surged 75.17% in 2022, then fell 15.65% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $3.9 billion in 2022, then gained by 1.88% to $4.0 billion in 2023, then increased by 0.22% to $4.0 billion in 2024, then fell by 5.46% to $3.8 billion in 2025, then fell by 0.45% to $3.8 billion in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.8 billion, $3.7 billion, and $3.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.